SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " Eli Lilly " 47 found 🔀 AI-powered Shuffle
Lilly's Jaypirca approved as first-line CLL therapy
Eli Lilly’s Jaypirca has won FDA approval for previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma.
ESPN announces 2026-27 Inside the NBA presented by Eli Lilly regular season schedule
ESPN today announced its 2026-27 regular season schedule for Inside the NBA presented by Eli Lilly. Produced by TNT Sports from its Atlanta studios, the
September Monthly Review: Health MCP Guy?
For all the time I spend talking about APIs and data exchange, this newsletter has had embarrassingly little interoperability of its own. It’s old-school SaaS, baby - UI or bust. Not all of that is my fault! Substack, for all its popularity, is (as mentioned before) really frustrating as my system of record. The primary user it optimizes towards is the reader, whose attention feeds the app, the Notes feed, and the recommendation network that Substack is actually selling. Health API Guy is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. Subscribe They’re falling into the same trap that Medium once sprinted into, albeit at a much more glacial speed. Younger generations may not remember (or never knew) it, but Medium once lured publications like The Ringer and Signal v. Noise onto its platform, only to lose them as it rebuilt itself around a paywall and an algorithmic feed. Substack’s original pitch circa 2020 was the antidote (you own your list), but every new feed feature chips away at it. I get it: writers are generic supply in the eyes of the Substack product team. Generic supply follows demand, so the consistent pressure on the PMs is to generate demand, which leads to every product cycle going toward discovery (Notes, recommendations, the app, live video). The end result lackluster author tools (laggy and broken analytics are truly crippling) all despite the premium price point. The archive is where it crosses from authorial gripes to actual reader impact, though. Across Substack and LinkedIn, I’ve published 1,218 posts and nearly 900,000 words since 2018. Substack’s native search can see only the 464 posts that live on Substack, and even there it’s woefully inadequate at surfacing relevant content (even for the guy who wrote it)! Readers have the same problem, writ large. Ask the Archive Fixing search (for both my readers and my own use) turned out to be extremely non-trivial, unfortunately: There’s no public API for readers to access content RSS exists for new content notification, but it only carries the 20 most recent posts and cuts paid ones off at the preview The only Substack MCP is an admin tool for analytics The export exists for authors, but it’s painfully awkward and slow. So I built something to work around that: the Health API Guy MCP. It’s a private MCP server holding the full text of everything I’ve written across Substack and LinkedIn. Add it to Claude or ChatGPT as a connector and you can ask things like: It pairs keyword search (for acronyms and case names, of which we have many) with semantic search. Every post is also labeled by topic, form, and court case, so you can pull a lawsuit’s (or multiple cases’) entire docket across Substack and LinkedIn in one query: Hail, Healthapiguyhydra This is also a bit of me eating my own cooking. I’ve spent the year arguing that headless healthcare is arriving and that developers want primitives over abstractions. Last week in Hail, Benihydra, I watched Salesforce plug its platform into Claude and bet that the records underneath outlive whatever interface sits on top: Salesforce must believe that the Hydra’s immortal head is the records, permissions, and business logic (in that they will survive whatever happens to the interface). It felt a bit hypocritical to keep my own archive behind a Substack search bar. The archive is the body. Substack is one head, and now whatever tool you might use is another. Will the EHRs follow my lead? Probably not imminently, but one can hope! Why Founding Members Only The MCP is available to Founding Member subscribers. A few reasons: It costs money and time to run. Hosting, the database, Clerk usage and AI compute for search and labeling are significant operational costs (that increase with usage). Substack gives me no way to automate access. There’s no API to check whether someone is a paid subscriber, so every user is manual operations for now. It’s a beta. We’ll need to improve things and parts will break. I’d rather they break for a small group of dedicated readers who will tell me about it. The Founding tier deserved a real benefit. Until now it was mostly a generous tip. Now it comes with something. If you’re already a Founding Member, reply to this email with the address you’d like provisioned. If you’re not and want in, upgrade here. Larger teams (such as companies) can get access too: group subscriptions at the Founding tier come with the group discount. The admin for the subscription can reply with the list of addresses to provision. Get 20% off a group subscription Pricing Founding membership is now a flat $200 a year, replacing the old suggested $150 that readers could adjust. Existing Founding Members will have access grandfathered in at their previous rate. Month in Review Articles Published Make Networks Dumb Again (Sep 11): AI is making old analog networks cheaper to use and flooding them with machine traffic in the process. A plea for agent-native rails with the intelligence at the endpoints, and for Washington to drag them to ubiquity. Interoperability, Unbuttoned (Sep 29): Interoperability is a series of workflows in a trenchcoat, and this post finally takes the trenchcoat off. A color-coded map shows which provider workflows went digital, which are fragmented, and which still run on fax. Video Content Antitrust’s System of Record Problem (Sep 3): The FTC’s investigation into Epic prompted a ninety-minute webinar, now posted with chapters and a smoothed transcript. We get into why market definition, missing B2B share data, and the SSNIP test leave antitrust poorly suited to systems of record, plus why information blocking may be doing more than any pending lawsuit. The Information Exchange: Cerner Milking Edition (Sep 18): This was so fucking fun. Ryan Tucker, Ryan Brickner, Brad Thorson, and I try an Around the Horn format, complete with points, penalties, and a mute button. We debate whether Oracle Health is dead, who would actually buy Cerner (IBM enters the chat), p(Doom), and why the front desk still hands you a clipboard. Regulatory Ask Not What Your Network Can Do (Sep 23): CDC’s RFI on public health data intermediaries lists use cases already served, unevenly, by eCR, lab reporting, IZ Gateway, and syndromic surveillance. The real opportunity sits in one question about AI: a network that can handle the next emergency without another interface project. Court cases Particle v. Epic: The Naughty Schoolteacher (Sep 4): After a summer-long vigil, the answer on Epic’s early summary judgment bid is two paragraphs and a remedial assignment. Particle advances to the next grade, and market definition gets another year of discovery. The Epic Discovery Files (Sep 8): Texas’s motions to compel arrive with a 251-page appendix of requests, objections, and meet-and-confer letters with Cravath. Inside: Epic using generative AI for document review, denied interoperability requests in scope, and Noerr-Pennington raised against lobbying discovery. Epic v. Health Gorilla: “Working as Designed” (Sep 9): Epic wants nothing to do with the data breach MDL, and explaining why puts fresh discovery on the public docket. The spiciest allegation: Health Gorilla told GuardDog to scrub its law firm business from its website instead of cutting off access. Veeva v. Epic: Legal Bypass Surgery (Sep 15): Veeva asks the Wisconsin Supreme Court to skip the Court of Appeals, while law professors and three policy groups line up as amici. Meanwhile, Epic’s lawyers apologize for another round of citation errors, including a quote that never existed. Texas v. Epic: Behind the Black Bars (Sep 17): The court portal served up Epic’s unredacted filings, revealing a $5 million document review budget and the AI workflow behind it. Also inside: the 200-plus company names Texas wants searched, and one very expensive Zoom invitation. OpenEvidence v. Doximity: Consequences Will Follow (Sep 25): OpenEvidence tells the court it will not comply with a discovery order, and its own lawyers at Quinn Emanuel say they won’t defend the choice. Add years of Slack reported unrecoverable, and Rule 37 sanctions come into view. Health Tech Keeps Choosing Violence (Sep 28): Doximity moves to end OpenEvidence’s case, Epic asks Texas to show its work, and a sleepy Audacious Inquiry patent fight sprouts antitrust and information blocking counterclaims. The main event is a long-sealed Cognizant v. Infosys ruling that hints where system of record antitrust claims can survive. EHRs One Verb for Oracle Health (Sep 14): Oracle’s earnings call quantifies every data center to the decimal point, while Oracle Health gets a single verb: “accelerate.” Panning the few healthcare mentions turns up an agentic care management system, a research-to-care ledger play, and the question of whether healthcare gets Larry’s patience. Epic’s Forretress Under Siege (Sep 30): Judy Faulkner tells a panel Epic paused hundreds of projects to harden its software and calls it a “shame,” while a spokesperson insists the roadmap hasn’t changed. Project Glasswing, a Pokémon-branded QAN sprint, and a trove of Jodel grievances reconcile the two Epics and preview the Jevons paradox coming for all software. Industry Analysis Scanning for a Network (Sep 1): Scan.com raises $220M to build the imaging network labs never got, speedrunning Zocdoc’s consumer-to-B2B pivot. Its wedge to network density may be the most American one available: personal injury litigation. The Front Desk Wants the Damn Whole Building (Sep 16): Hello Patient buys Converse Health, pushing its AI front desk into referrals, chart work, and prior auth. The copilot categories keep blurring, and your distribution partner is still your final boss. Cross-industry Comparisons A Different Patchwork Quilt (Sep 10): Healthcare loves to envy open banking, but the US version has no mandate, a toll booth at Chase, and data quality problems of its own. The grass isn’t greener; it’s another American patchwork quilt, and perhaps a worse one. Hail, Benihydra (Sep 21): Salesforce brings its platform into Claude, Slack, and its own agent, inviting the interfaces that might replace it. Cut off one head and more grow back, so long as the records underneath stay put. Living on A Trade Secret Prayer (Sep 22): Six credit unions are suing Fiserv, the Epic of core banking, by claiming their own member records as trade secrets. Banking has no Cures Act, so its lawyers reach for legal alchemy that healthcare has already tried. Other News None this month External Media Nabla Accelerate NYC: I kicked off fall conference season at Nabla’s Accelerate event in New York, where Delphine Groll opened by asking the room to picture the company it wants to become and the one it doesn’t. I liked her framework of bureaucracy, fear, and ego as the blockers. I also love vendor conferences/events in general - different vibe than industry biggies. Healthcare 101 with Nikhil Krishnan: I briefly guest lectured Out-Of-Pocket’s Healthcare 101 class. Appreciated Nikhil’s takeaways cover whether AI doctors can query HIEs, why healthcare’s data-liberation rules beat most industries’, and the hi-res graphic is in the comments. HCN: Epic Probed by the FTC: I joined the HCN guys to talk through the FTC’s investigation into Epic. Cedric’s new hairdo was an unexpected plot twist. The episode also covers MFN drug pricing, healthcare M&A and Eli Lilly’s acquisition streak. Fall Conferences: At eHealth Exchange’s Annual Meeting in Austin on Oct 27, I’ll moderate a panel on the tensions between AI, HIEs, and timely patient access with Jean Ross (Primary Record), Therasa Bell (Kno2), Byron Crowe (Doctronic), and Michael Marchant (Freenome). Here’s the rest of my schedule if you want to meet up: CommonWell (Redwood Shores, CA): Oct 13-14 Will be participating in a fun Jeopardy event Open@Epic (Madison, WI): Oct 20-23 Will be enjoying Verona, Willy Street, and other local adventures eHealth Exchange and Sequoia Project (Austin, TX): Oct 27-29 Yeehaw HLTH (Vegas): Nov 15-18 Groundhog Day, Venetian Edition RSNA (Chicago): Nov 30-Dec 2 See me at “Governing AI in Breast Imaging: What Health Systems Are Actually Doing” Digital Health Counsel 2026 AI Summit (Seattle): December 2-3 Will likely be speaking to a bunch of lawyers about information blocking Posts I Liked ChatGPT’s Epic integration: game changer or nothing burger?: Joshua Liu, MD offers five thoughts on OpenAI’s Epic launch, starting from the point that it rides the same open APIs available to anyone. He argues read-only access leaves ordering to Art and the ambient startups, and asks why HCA is piloting it alongside Commure. He’s sorta a must-follow at this point - consistently excellent, thought-provoking takes. Epic, Lilly, and the Discovery pass: Seth Chaney reads Epic’s first major Discovery deal (with Eli Lilly), as well as its revised developer terms on commercial displays, as the pipe finally opening between EHRs and pharma. Life sciences and health continue to collide. Scott Rossignol on EHR payer platforms and ePA fees: Scott argues the top ambulatory EHR vendors are turning the prior auth mandate into a per-member-per-year toll on payers, for an API whose operating cost has nothing to do with covered lives. His fix is two lines of regulatory text: put the CRD/DTR/PAS certification criteria in the Base EHR definition, and bring payer-facing ePA connectivity under § 170.404’s cost-based fee rules. It’s a good solution. Health API Guy is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. Subscribe
‘It’s problematic’: Concern as Vogue World event sponsored by ‘skinny jabs’ maker
Partnership between Mounjaro maker Eli Lilly and fashion giant, suggests thinness is an aspiration says critics
‘It’s problematic’: Concern as Vogue World event sponsored by ‘skinny jabs’ maker
Partnership between Mounjaro maker Eli Lilly and fashion giant, suggests thinness is an aspiration says critics
Brain health is focus on World Alzheimer's Day
Eli Lilly and Planet Harvest bring brain healthy food boxes delivered to seniors on Sept. 21, 2026 at Avon Tower in Rochester Hills, Mich.
Secret contracts reveal undisclosed terms in Trump’s drug-pricing deals
Agreements with Pfizer and Eli Lilly include tariff protections, overseas pricing inducements and broad confidentiality clauses.
How Hollywood Shapes Our Understanding of Health
A study sponsored by Eli Lilly and Company (Lilly) shows that chronic illness is historically underrepresented on screen, while a growing coalition of studios, researchers, and patient advocates work to change that reality.
Luma locks down 15-year, $410M fund for life science investments
Luma Group today announced the final close of its inaugural life sciences venture capital fund, totaling $410 million. The New York-based investment firm has had a grip on life sciences since its founding in 2023. The funds unveiled today, dubbed LumaBio Fund I, include investments that have already been made into more than 10 biotechs. They include the likes of eye disease-focused Character Biosciences, rebranded Belgian biotech Coultreon Biopharma and cellular rejuvenation company Altos Labs. The fund saw early success when one of the companies it co-founded, called Vaccine Company, was picked up by Eli Lilly earlier this year for up to $1.55 billion. The acquisition of the in vivo nanoparticle technology-focused biotech formed part of a trio of vaccine buys for the Big Pharma, which has itself been on a prolonged spending spree in 2026. Luma's fund is structured as a 15-year investment with plans to support groundbreaking science and support companies through key milestones from discovery to commercialization, Luma explained in the release. "We founded Luma Group on the belief that extraordinary science, supported by patient, long-term capital, has the power to improve millions of lives," Joshua Fink, founder and managing member of Luma Group, said in the release. "This fund represents more than capital—it is a commitment to partnering with extraordinary innovators as they translate visionary science into life-changing medicines."
FDA approves tirzepatide for reducing cardiovascular risk in adults with type 2 diabetes
The popular drug, sold by Eli Lilly and Company under the brand name Mounjaro, has been at the center of many cardiology trials over the years. It is now the first dual GIP and GLP-1 hormone receptor agonist approved by the FDA for this indication.
UNICEF’s Support for Primary Health Care Helps Children with NCDs Reclaim Their Futures
With support from Eli Lilly and Company to UNICEF USA, UNICEF is helping strengthen primary health care for children living with NCDs in Bangladesh.
CVS Health to Revamp Weight Program in Eli Lilly Partnership
CVS Health said it will revamp its weight management program through a partnership with Eli Lilly as the company lifted its full-year outlook and reported a nearly threefold increase in its second-quarter profit.
CVS blows past estimates, hikes guidance as insurance unit continues to improve
CVS also announced a new collaboration with Eli Lilly that will make Zepbound and Foundayo accessible to eligible patients on the CVS Health app.
Novo Nordisk sues GLP-1 rival Eli Lilly over claims of false advertising
Novo Nordisk filed a lawsuit claiming Eli Lilly ran “false and materially misleading” advertisements that ignore recent data. According to Lilly, though, its message is "truthful" and "grounded in the most direct scientific evidence available."
Lilly’s $2.8 Billion Bet on Psychedelics Buys Science That Conventional Trial Infrastructure May Not Be Able to Run
Eli Lilly acquires AtaiBeckley for $2.8B, but the FDA's final psychedelic trial guidance reveals an operational crisis Big Pharma hasn't priced in.
The market for psychedelic drugs to treat mental health conditions gets a big buy signal
Eli Lilly's acquisition of psychedelic drug maker AtaiBeckley extends Big Pharma's embrace of a stigmatized class of medications for treating mental health.
Health Brief: MAHA and Trump collide on pesticides
Plus: Eli Lilly dives into psychedelics
Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and AtaiBeckley Inc. (Nasdaq: ATAI), a clinical-stage biopharmaceutical company developing innovative...
Eli Lilly is reinventing the pharma business
The world’s largest drugmaker is betting big on preventive medicines—and learning from big tech
Impressive growth of Eli Lilly's obesity business is coming from all over the world
Eli Lilly's international GLP-1 business is booming, giving investors another reason to stick with the stock.
Supreme Court rules in weedkiller cancer case
Dems want to unmask Eli Lilly's obesity drug user, a new genome-editing tool raises ethics questions, and more health news
Hims' obesity drug business may get boost as employers drop coverage
Telehealth provider Hims and Hers Health may get a boost next year from employers dropping coverage of weight-loss drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound and Foundayo to rein in costs, investors and analysts say.
Health Care Roundup: Market Talk
Find insight on Eli Lilly, AstraZeneca, Sandoz and more in the latest Market Talks covering Health Care.
Abridge inks deals with Nvidia and Lilly
Abridge announced new deals with Eli Lilly and Nvidia as it aims to gain an edge in a competitive market.
UK health regulator approves Novo Nordisk's weight-loss pill
Britain's medicines regulator approved Novo Nordisk's weight-loss pill on Thursday, giving patients a new needle-free treatment option and bolstering the Danish drugmaker's first-to-market lead against U.S. rival Eli Lilly .
3 ways GLP-1 drugs could be getting better
Drug companies are racing to catch up to Eli Lilly and Novo Nordisk, seeking to require fewer shots or reduce side effects.
Lilly, BioNTech Warn German Health Reforms Could Hurt Investment
Eli Lilly & Co. and BioNTech SE joined a growing chorus of drugmakers warning that proposed healthcare reforms in Germany risk undermining investment the country.
Eli Lilly's top dealmaker says don't be surprised to see more M&A that pushes Lilly into new areas
Eli Lilly's new top dealmaker explains how the company changed its approach to M&A now that it's the most valuable pharmaceutical company in the world.
Illinois hospitals urge Pritzker to quickly sign bill before Eli Lilly cuts off drug discounts
Illinois’ hospital association contends the move by Eli, which has also been threatened by the other large, global GLP-1 manufacturer, Novo Nordisk, is simply an unnecessary roadblock.
An experimental GLP-1 pushes the limits of weight loss. There are risks.
Eli Lilly is developing the the most powerful GLP-1 drug yet. But how much weight loss is too much?
Healthy Returns: Eli Lilly makes a new push into vaccines – here’s what to know
The drugmaker announced it will buy three privately held vaccine makers in deals worth almost $4 billion combined.
Eli Lilly to acquire Seattle-area vaccine maker for $1.5 billion
The acquisition of Curevo Vaccine, which develops vaccines for shingles and chickenpox, was announced Tuesday.
Watch Lilly Gets Back Into the Vaccine Business With New Deals
Eli Lilly & Co. is buying three clinical-stage vaccine developers for as much as $3.8 billion as it looks to become a leader in infectious diseases. The drugmaker has been using cash from its obesity drugs to expand into other disease areas. Bloomberg's Gerry Smith reports.
The Science Behind the Quest for a Non-Peptide Oral Weight Loss Drug
Not only does it have a tongue-twisting name, “orforglipron” has a complex molecular structure that made its synthesis very challenging. A massive effort by chemists at the Eli Lilly pharmaceutical
New obesity drug helped patients lose up to 85 pounds in trial
A new experimental obesity drug from Eli Lilly helped patients lose an average of about 85 pounds in a late-stage clinical trial. Duke Health expert Dr. Susan Spratt says the results are reaching levels typically only seen with gastric bypass surgery.
Lilly, Caitlin Clark Foundation, and Musco Lighting open three community sports courts in Indianapolis, expanding year-round access for youth
/PRNewswire/ -- The Caitlin Clark Foundation, in partnership with Eli Lilly and Company (NYSE: LLY) and Musco Lighting, has opened three new multi-sport...
Eli Lilly & Company CEO reflects on business’ 150-year history in Indianapolis
INDIANAPOLIS — This May marks 150 years since the founding of Eli Lilly & Company, which has always been based in the heart of Indianapolis. “(Colonel Eli Lilly) was driven by purpose, wh…
Eli Lilly shoots for health in new Caitlin Clark ad campaign
Flashy three pointers; top athletes playing under the lights; cameras focusing in on our celebrity making a game-winning shot—all elements you’d typically associate with a Big Pharma ad featuring a | Flashy three pointers; top athletes playing under the lights; cameras focusing in on our celebrity making a game-winning shot—all elements you’d typically associate with a Big Pharma ad featuring a major athletic celebrity. Not for Eli Lilly though.
Sun Pharma, Eli Lilly Lead Latest Rush of Healthcare M&A
The value of biopharma M&A has more than doubled his year.
Amazon Pharmacy to Offer Eli Lilly and Company’s New GLP-1 Pill Foundayo via Same-Day Delivery
Amazon Pharmacy (NASDAQ: AMZN), a full-service digital pharmacy that offers fast medication delivery directly to customers' homes, now offers Eli Lilly and C...
Health Care Roundup: Market Talk
Find insight on Eli Lilly, Hansoh Pharmaceutical Group and more in the latest Market Talks covering the Health Care sector.
Lilly finds impurity in compounded version of its weight-loss drug, warns of health risks
Compounded weight-loss drugs that contain vitamin B12 and the main ingredient in Eli Lilly's Zepbound could present health risks to consumers due to a previously unidentified impurity caused in the preparation, the U.S. drugmaker said in a public letter released on Thursday.
Eli Lilly's orforglipron beats Novo Nordisk's GLP-1 pill in tests
Eli Lilly released new data on its oral pill, orforglipron, Thursday, showing it's almost as good as Ozempic. The pill may be available this spring.
Healthy Returns: What’s next for Novo Nordisk’s next-generation obesity drug CagriSema after trial miss
The Danish drugmaker released late-stage data showing that the upcoming injection CagriSema failed to match the weight loss of Eli Lilly’s Zepbound.
Health Care Roundup: Market Talk
Find insight on Gilead Sciences, Arcellx, Eli Lilly and more in the latest Market Talks covering Health Care.
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.
Eli Lilly is the leader in the GLP-1 space, but here's another GLP-1 stock and a medical device maker to consider.
Forbes Daily: Gen Z Leaders Now Dominate The Forbes 30 Under 30
Today’s Forbes Daily newsletter covers the new 30 Under 30 list, Sam Altman’s OpenAI memo, NYC casino proposals move forward, Eli Lilly slashes Zepbound costs and more.